China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 7.73
(0.39%)
HKD 7.73
(0.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.53 Billion CNY | 37.3% |
| 2022 | 1.84 Billion CNY | 41.99% |
| 2021 | 1.3 Billion CNY | -8.23% |
| 2020 | 1.41 Billion CNY | 4.79% |
| 2019 | 1.35 Billion CNY | 40.21% |
| 2018 | 966.01 Million CNY | 14.43% |
| 2017 | 844.15 Million CNY | 0.66% |
| 2016 | 838.58 Million CNY | -2.16% |
| 2015 | 857.13 Million CNY | -15.5% |
| 2014 | 1.01 Billion CNY | -22.49% |
| 2013 | 1.3 Billion CNY | 75.33% |
| 2012 | 746.41 Million CNY | 3.38% |
| 2011 | 722.02 Million CNY | -2.77% |
| 2010 | 742.56 Million CNY | 35.54% |
| 2009 | 547.84 Million CNY | 89.08% |
| 2008 | 289.74 Million CNY | -14.65% |
| 2007 | 339.46 Million CNY | 42.34% |
| 2006 | 238.49 Million CNY | 10.93% |
| 2005 | 215 Million CNY | 60.28% |
| 2004 | 134.14 Million CNY | -21.75% |
| 2003 | 171.43 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 2.53 Billion CNY | 0.0% |
| 2023 Q2 | 2.26 Billion CNY | 0.0% |
| 2023 FY | 2.53 Billion CNY | 37.3% |
| 2022 FY | 1.84 Billion CNY | 41.99% |
| 2022 Q2 | 1.39 Billion CNY | 0.0% |
| 2022 Q4 | 1.84 Billion CNY | 0.0% |
| 2021 Q2 | 1.08 Billion CNY | 0.0% |
| 2021 FY | 1.3 Billion CNY | -8.23% |
| 2021 Q4 | 1.3 Billion CNY | 0.0% |
| 2020 FY | 1.41 Billion CNY | 4.79% |
| 2020 Q4 | 1.41 Billion CNY | 0.0% |
| 2020 Q2 | 1.59 Billion CNY | 0.0% |
| 2019 FY | 1.35 Billion CNY | 40.21% |
| 2019 Q2 | 932.68 Million CNY | 0.0% |
| 2019 Q4 | 1.35 Billion CNY | 0.0% |
| 2018 Q4 | 966.01 Million CNY | 0.0% |
| 2018 FY | 966.01 Million CNY | 14.43% |
| 2018 Q2 | 858.81 Million CNY | 0.0% |
| 2017 Q4 | 844.15 Million CNY | 0.0% |
| 2017 Q2 | 761.33 Million CNY | 0.0% |
| 2017 FY | 844.15 Million CNY | 0.66% |
| 2016 FY | 838.58 Million CNY | -2.16% |
| 2016 Q4 | 838.58 Million CNY | 0.0% |
| 2016 Q2 | 697.43 Million CNY | 0.0% |
| 2015 FY | 857.13 Million CNY | -15.5% |
| 2015 Q4 | 857.13 Million CNY | 0.0% |
| 2015 Q2 | 688.55 Million CNY | 0.0% |
| 2014 Q4 | 1.01 Billion CNY | 0.0% |
| 2014 FY | 1.01 Billion CNY | -22.49% |
| 2014 Q2 | 1.39 Billion CNY | 0.0% |
| 2013 Q2 | 623.32 Million CNY | 0.0% |
| 2013 FY | 1.3 Billion CNY | 75.33% |
| 2013 Q4 | 1.3 Billion CNY | 0.0% |
| 2012 Q4 | 746.41 Million CNY | 0.0% |
| 2012 FY | 746.41 Million CNY | 3.38% |
| 2012 Q2 | 635.18 Million CNY | 0.0% |
| 2011 Q2 | 725.47 Million CNY | 0.0% |
| 2011 Q4 | 722.02 Million CNY | 0.0% |
| 2011 FY | 722.02 Million CNY | -2.77% |
| 2010 Q4 | 742.56 Million CNY | 0.0% |
| 2010 FY | 742.56 Million CNY | 35.54% |
| 2010 Q2 | 606.57 Million CNY | 0.0% |
| 2009 FY | 547.84 Million CNY | 89.08% |
| 2009 Q4 | 547.84 Million CNY | 0.0% |
| 2008 FY | 289.74 Million CNY | -14.65% |
| 2007 FY | 339.46 Million CNY | 42.34% |
| 2006 FY | 238.49 Million CNY | 10.93% |
| 2005 FY | 215 Million CNY | 60.28% |
| 2004 FY | 134.14 Million CNY | -21.75% |
| 2003 FY | 171.43 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -1684.642% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 64.951% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -1390.094% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -257.812% |
| Qianhai Health Holdings Limited | 94 Million HKD | -2601.217% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -173.015% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -180.956% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -281.615% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -268.19% |
| SSY Group Limited | 4.49 Billion HKD | 43.497% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -592.353% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -132.851% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 98.493% |